Oslo, Norway, 2 December 2020 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will today present data from its melanoma and mesothelioma trials in an online webcast at 10:00am CET.
With reference to the press release issued 1 December 2020 (see link here), Targovax will present data from its phase 1 trial combining ONCOS-102 and the anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda) in patients with advanced, unresectable melanoma who have had disease progression despite treatment with anti-PD1 CPI.
Data from the randomized phase 1/2 trial of ONCOS-102 in combination with standard-of-care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM), which was released 24 November 2020 (see link here), will also be presented in the webcast.
The webcast starts at 10:00am CET and you can join the webcast here. It will be possible to ask questions during the presentation. A replay of the webcast will be available in the Investor section under “Presentations” after the event.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Kim Sutton Golodetz – LHA Investor Relations (US)
Phone: +1 212-838-3777
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients with targeted therapeutic cancer immunotherapies. The Group’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile. Further, the products are well positioned for combinations with other treatment approaches, including other immunotherapies, surgery, radiation and chemotherapy.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and colorectal cancer and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.